Raymond U. Osarogiagbon, MBBS, FACP

Multidisciplinary Thoracic Oncology Program, Baptist Centers for Cancer Care, Memphis, TN, USA

Dr. Osarogiagbon is a Research Professor at the University of Memphis School of Public Health, a Research Member of the Vanderbilt Ingram Cancer Center, and a member of the Lung Cancer Disparities Center of the Harvard School of Public Health. He is board certified in the Internal Medicine subspecialties of Hematology and Medical Oncology, a Fellow of the American College of Physicians and belongs to several professional societies including the Alpha Omega Alpha Honor Medical Society, American Society of Clinical Oncology, American Society of Hematology, the Cardiothoracic Surgery Network, and the International Association for the Study of Lung Cancer.

Dr. Osarogiagbon currently serves as Director of the Multidisciplinary Thoracic Oncology Program at the Baptist Cancer Center, in Memphis, Tennessee, the dominant clinical oncology service provider in the demographically heterogeneous tri-state region of East Arkansas, North Mississippi and West Tennessee, which has some of the highest lung cancer incidence rates in the US. He also serves as Director of the Thoracic Oncology Research (ThOR) Group of the Baptist Cancer Center and is the Principal Investigator of two major ongoing regional projects: a US National Institutes of Health R01-funded regional quality improvement project titled ‘Dissemination and implementation of a corrective intervention to improve mediastinal lymph node examination in resected lung cancer’ (R01 CA172253-01); and the Patient Centered Outcomes Research Institute-funded comparative effectiveness study of multidisciplinary v serial care for lung cancer titled ‘Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology’(IH-1304-6147).

Dr. Osarogiagbon’s research interests center around improving population-based systems of care, improving accuracy of cancer staging and evaluating the biologic drivers of outcome differences in potentially curable lung cancer. He is an ad-hoc member of the Health Services Organization and Delivery study section of the US National Institutes of Health and a member of the International Association for the Study of Lung Cancer membership committee.